NEJM Releases Bayer Key Phase 3 Clinical Results: DKD Progress Slows 18% CV Risk reduction by 14%
Time of Update: 2020-11-11
) by overactivated salt corticosteroids. Finerenone is a research nonsteroidal selective salt corticosteroid (MR) antagonist that reduces the harmful effects of overactivation of salt corticosteroids. FIDELIO-DKD is a randomized, double-blind
Micropropagation and Organogenesis of Anthurium andreanum Lind cv Rubrun
Time of Update: 2020-11-10
We also describe a detailed method for the histological analysis of callus tissue and a vitro plants acclimatization protocol.
Oxford University study of 420,000 people: The earlier you correct this bad habit, the lower the risk of CV death
Time of Update: 2020-11-09
death from cardiovascular disease than people who never smoke, and the lower the risk of starting smoking, the lower the risk; researchers from the University of Oxford in the United Kingdom followed up with more than 420,000 subjects
When CVS announced that it would replace biological analogues in its health care catalog from next year
Time of Update: 2016-08-09
The company also said it no longer reimbursed toujeo, Sanofi's new diabetes drug.
CVs, an American drugstore chain giant, is holding hands with three telemedicine companies
Time of Update: 2015-08-28
Source: health industry on August 26, 2015, CVS health, an American drugstore giant, announced that it would cooperate with three major telemedicine companies: American well
Gilead can't help but fight back: CVS supplies Gilead hepatitis C drugs exclusively
Time of Update: 2015-01-07
Source: e-medicine Facebook 2015-1-7 CVS said that unless medical treatment requires special circumstances or prior authorization, the all oral hepatitis C drug combination viekira
CVs, the second largest pharmacy in the United States, spent $2.1 billion on medical and health services
Time of Update: 2013-11-28
Source: financial China News Agency announced on November 28, 2013 that CVS Caremark, the second largest pharmacy group in Dalian in the United States, spent $2.1 billion to acquire Coram, a special injection service provider, from Apria healthcare group.